Trial
NCT03070002
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
Amgen; National Cancer Institute (NCI)
Condition
Breast Carcinoma Metastatic in the Bone
Intervention
Denosumab
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-20